Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC By Ogkologos - July 29, 2025 544 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NeoCOAST-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection MOST POPULAR Reunión anual de la American Society of Clinical Oncology de 2022:... June 6, 2022 NECTIN4 Amplification Predicts Response to Enfortumab Vedotin and Long-Term Survival in... May 8, 2024 Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After... February 16, 2022 Veteran and His Loyal Dog Pass Away Within Hours Of Each... May 21, 2020 Load more HOT NEWS Efficacy of Rituximab Maintenance in Patients with Mantle Cell Lymphoma Who... Body Location May Influence Fate of Cells with Cancer-Causing Mutations Adding Olanzapine to Standard Triple Antiemetic Therapy for the Prevention of... Bagel Shop Owner Shaves Head To Support 10-Year-Old Customer
